Patients with existing heart or kidney disease may benefit from starting SGLT-2 inhibitors therapy, while those with a higher risk of developing these conditions, such as obese patients and those with no cardiogenic stroke, may benefit more from GLP-1 RAs. This evidence concerns the gene GLP1R and kidney disorder.